Cambrex

Cambrex

Global CDMO for drug substances

Overview

Cambrex is a global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, plus analytical and IND enabling services. It uses a range of specialized technologies—such as continuous flow chemistry, handling of controlled substances, liquid-phase peptide synthesis, solid-state science, material characterization, and production of highly potent APIs—to develop and manufacture drug substances for clients. The company differentiates itself with over 40 years of experience, a staff of about 2,000 experts, and a global footprint in North America and Europe, offering end-to-end capabilities from early development through commercial-scale manufacturing. Its goal is to help clients bring new medicines to market by delivering integrated, reliable drug substance development and manufacturing and related analytical support.

About Cambrex

Simplify's Rating
Why Cambrex is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Industrial & Manufacturing

Biotechnology

Healthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

East Rutherford, New Jersey

Founded

1981

Get referred to Cambrex

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cambrex started Milan's $30 million R&D center on August 11, 2026.
  • Iowa approved $150 million for Charles City, adding 104 jobs in 2028.
  • The March 23, 2026 Iowa engineering milestone advances 140,000-liter capacity by 20 percent.

What critics are saying

  • Charles City's late-2026 groundbreaking and 2028 jobs depend on flawless execution.
  • Milan's 2027 R&D build risks overruns, delaying customer transfers and revenue.
  • A failed Charles City ramp would strand $120 million investment and hand projects to Lonza.

What makes Cambrex unique

  • Cambrex owns specialized small-molecule capacity across Charles City and Milan.
  • Its portfolio spans HPAPI, controlled substances, peptides, and complex chemistry.
  • Permira-backed capital supports large, site-specific expansions without public-market distraction.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$120M

Above

Industry Average

Funded Over

1 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison
Coming Soon

Benefits

Health Insurance

401(k) Retirement Plan

Life Insurance

Tuition Reimbursement

Elder Care Support

Stock Price

Company News

PR Newswire
Aug 11th, 2026
Cambrex Milan celebrates its 80th anniversary with the construction of a new $30 million R&D center.

Cambrex Milan celebrates its 80th anniversary with the construction of a new $30 million R&D center. Aug 11, 2026, 06:41 ET EAST RUTHERFORD, New Jersey, Aug. 11, 2026 /PRNewswire/ - Cambrex, a leading contract development and manufacturing organization (CDMO), announced today the start of construction of a new research and development (R&D) center at its Milan, Italy site. This $30 million investment will strengthen capabilities in advanced analytical development and process research and development, while modernizing several production sites, confirming Cambrex's commitment to supporting the development of the most complex small molecules in the pharmaceutical industry. The expansion of the Milan R&D center is expected to be completed in the second half of 2027. To anticipate its growth and meet the growing demand for CDMO services, Cambrex has also acquired additional land adjacent to the site, thus securing the capacity needed to grow and innovate in the years to come. Cambrex Profarmico's Milan site, which celebrates its 80th anniversary this year, can boast a long tradition of supporting the development and manufacture of pharmaceutical products for its international clientele. The Milan team recently gathered to celebrate this important milestone, reflecting on eight decades of scientific achievements and commitment to human health. Claudio Russolo, chief operating officer at Cambrex, said: "The launch of work on this new facility says a lot about the enduring legacy and expertise of our Milan team. For 80 years, this site has been a pillar of the pharmaceutical industry in Europe. With this expansion, we are investing not only in new technologies and skills, but also in the future of our employees and partners." This investment builds on the scientific expertise and industrial excellence that are the hallmark of Cambrex's reputation, while preparing the company to enter a new phase of growth. By expanding its R&D capabilities in Milan, Cambrex strengthens its ability to address the growing complexity of today's small molecule therapies. About Cambrex Cambrex is one of the world's leading contract development and manufacturing organizations (CDMO). The company offers development and manufacturing services for active substances throughout the drug lifecycle, as well as comprehensive analytical services. With more than 45 years of experience and a team of 2,000 experts serving international clients in North America and Europe, Cambrex offers a range of technologies and specialized skills in the field of drug substances, including continuous flow production, controlled substances, peptide synthesis, solid-state science, biocatalysis, material characterization, complex compound synthesis, and highly potent active pharmaceutical ingredients (HPAPI).

PR Newswire
Aug 11th, 2026
Cambrex Milan celebrates 80th anniversary with construction of new $30 million R&D facility.

Cambrex Milan celebrates 80th anniversary with construction of new $30 million R&D facility. Aug 11, 2026, 06:00 ET EAST RUTHERFORD, N.J., Aug. 11, 2026 /PRNewswire/ - Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the start of construction on a new research and development (R&D) facility at its Milan, Italy site. This $30 million investment will add advanced analytical development and process R&D capabilities, alongside upgrades to multiple production plants, reinforcing Cambrex's commitment to supporting the pharmaceutical industry's most complex small molecule development. The Milan R&D expansion is expected to be completed in the second half of 2027. To accommodate future growth and rising demand for CDMO services, Cambrex has also acquired additional land adjacent to the site, ensuring the capacity to expand and innovate for years to come. The Cambrex Profarmico Milano site, which marks its 80th anniversary this year, has a distinguished legacy of supporting pharmaceutical development and manufacturing for its global client base. The Milan team recently gathered to celebrate this milestone, reflecting on eight decades of scientific achievement and dedication to advancing human health. Claudio Russolo, Chief Operating Officer at Cambrex, commented: "Breaking ground on this new facility is a testament to the enduring legacy and expertise of our Milan team. For 80 years, this site has been a cornerstone of pharmaceutical manufacturing in Europe. With this expansion, we are investing not only in new technologies and capabilities, but in the future of our people and our partners." The investment builds on Cambrex's legacy of scientific expertise and manufacturing excellence while positioning the company for its next chapter of growth. By expanding R&D capabilities in Milan, Cambrex is strengthening its ability to address the increasing complexity of today's small molecule therapies. About Cambrex Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical services. With over 45 years of experience and a team of 2,000 experts servicing global clients from North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, peptide synthesis, solid-state science, biocatalysis, material characterization, complex synthetics, and highly potent APIs.

Winn-Worth Bet Co.
Jul 27th, 2026
CCADC accreditation: A national seal of approval for Floyd County's economic future.

CCADC accreditation: A national seal of approval for Floyd County's economic future. 27 Jul 2026 News, Blog For nearly 30 years, Tim Fox has played a leading role in all matters pertinent to economic development in Floyd County, IA. As CEO of Charles City Area Development Corporation (CCADC), Fox has helped recruit new companies to the region, assisted existing businesses in growing, and overseen various projects "from the ground up," as he put it. So suffice it to say that in Floyd County and Charles City, Fox's reputation, and that of CCADC by proxy, precedes him. However, firm existing credentials didn't stop Fox from pursuing Accredited Economic Development Organization (AEDO) status from the International Economic Development Council (IEDC). "It was important to seek accreditation in verifying that we are providing services at a highly competent level, managing stakeholder expectations reliably, and demonstrating overall proficiencies in the practice of economic development," Fox said. "AEDO accreditation requires that we master fiscal, organizational, human resources, community outreach, board of directors training and ethical considerations." AEDO accreditation: process & benefits. Achieving AEDO accreditation involves a rigorous process featuring comprehensive peer reviews, extensive documentation, on-site evaluations, and more to ensure organizations adhere to best practices in governance, strategy, and community engagement. In short, an applying organization better have its ducks in a row. To be sure, elements of the application process proved challenging, but as Fox navigated it for the first time in September of 2021, it turned out to be confirmation that CCADC was organized and running smoothly. "The experience proved quite enjoyable," Fox said. "The documentation factor can seem daunting at first, but what you soon realize is that if your agency is being operated equitably and efficiently, it has already mastered the bulk of verification indices. The on-site evaluation was particularly instructive, in that the community is being evaluated in concert with developmental agency scrutiny." Fox takes particular pride in CCADC's accreditation due to its size. Aside from Fox, CCADC employs just one other person: administrative specialist Christy Laube. Furthermore, among corresponding AEDO county/province populations, Floyd County ranks as the smallest, at about 15,000 residents. For comparison, Iowa's other accredited organization serves Lee County, which has a population of approximately 32,300. Economic outlook in Charles City & Floyd County. Fox has good reason to be optimistic about the current economic outlook in Charles City and Floyd County. For starters, Charles City will be the location of an expanded facility of pharmaceutical giant Cambrex, representing a capital investment of nearly $150 million, which will create over 100 new high-wage, high-skill jobs. Cambrex specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates. Their expansion will heighten production capacity by 40%, rendering it the largest API manufacturer in the United States. In addition, CCADC's long-term strategic plan, spanning job creation, wage increases and improvements in quality of life, is bearing fruit across the board. "Our main mission is creation and retention of high-quality jobs, and our investments have paid off," Fox said. "In 2024, Floyd County's average manufacturing wage eclipsed the remainder of north-central Iowa by fully 20%. Floyd County workers earned, on average, $12,363 more per annum, or $5.94 an hour, than in cohort counties." "As CCADC has matured as an organization, its work plan has grown to include such matters as housing and childcare and has met with substantive successes." Part of what's worked for Fox and CCADC has been an approach that doesn't always favor huge projects at the expense of local industries. Maintaining a level playing field helps Fox foster diverse regional economic development. "Looking out for everyone has served our community well and imposed structure in decision-making processes," he said. "CCADC strives to fully explain decision-making protocols as is conceivable. It is our goal to be the economic development policymaking clearinghouse in greater Floyd County."

Hubbard Broadcasting
May 20th, 2026
Factory expansion brings jobs to Charles City.

Factory expansion brings jobs to Charles City. Factory expansion to bring jobs to Charles City. 3 hours ago (ABC 6 News) - A facility expansion of pharmaceutical manufacturer Cambrex is expected to create 104 new jobs in 2028, upon its completion. The New-Jersey based company already has a 45-acre campus in Charles City, but construction is expected to start on a new 7,700-square-foot facility June 1. The Iowa Economic Development Authority, which approved the expansion May 16, said this $150 million investment will increase factory production by 40 percent. Charles City Mayor Dean Andrews said he hopes new jobs from Cambrex will draw people to move to Charles City, and that he has housing projects expected to be completed at the same time as the factory. "They're good quality jobs with good benefits," Andrews said. "So a real plus for us." The facility produces pharmaceutical ingredients used in treatments for cancer, HIV, ADHD and more.

SpecChem
Mar 30th, 2026
Cambrex hits engineering milestone.

Cambrex hits engineering milestone. 30th March 2026 Submitted by: Andrew Warmington Cambrex has completed initial engineering studies for its new, large-scale API plant in Charles City, Iowa. Groundbreaking is scheduled to take place in late 2026. The company said that this milestone "marks significant progress toward the company's previously announced $120 million investment in expanding its US API manufacturing capabilities". The expansion will add 20% to the site's large-scale manufacturing capacity via a new plant with 140 m3 of capacity, including large- and mid-scale reactors, advanced Hastelloy agitated filter-dryers and enhancements to existing suites. It is also designed to support complex chemistry, including controlled substances, HPAPIs and commercial-scale liquid phase peptide manufacturing.

Recently Posted Jobs

Sign up to get curated job recommendations

Cambrex is Hiring for 47 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →